030-08198

Greenville Hospital / 1825 Kennedy Boulevard / Jersey City, N.J. 07305 / (201) 547-6100

June 22, 1988

U.S. Nuclear Regulatory Commission
Region I
631 Park Avenue
King of Prussia, Pa. 19406

Gentlemen:

Please amend our License No. 29-14859-01 in the following manner:

Effective September 1, 1988 delete from our license the following doctors:

Burton Garfinkel, M.D.
Abraham Ruiz, M.D.
Hillel J. Karp, M.D.
Eileen Concannon, M.D.
E. Lukas Charles, M.D.
Robert Port, M.D.
Irwin Hirshberg, M.D.
Bernard Greenspan, M.D.

Add to our current license:

John V. Cholankeril, M.D.

Log: Jul. 6 L
Remitter:
Check #: 000742
Amount: $120
Fee Category: 7C
Type of Fee: AMD
Date Check Rec'd: 8/15/88
Date Completed: 8/15/88
By: S. Lamberg

A copy of the byproduct material license of which Dr. Cholankeril is presently an authorized user is enclosed.

Yours very truly,

Lawrence P. Ward
Administrator

Enc.

Rec'd L7mB
7/9/88

JUL 14 1988

Greenville Hospital
ATTN: Mr. Lawrence P. Ward
Administrator
1825 Kennedy Boulevard
Jersey City, NJ 07305

Gentlemen:

This refers to your letter dated June 22, 1988, for an amendment to Materials License 29-14859-01.

An amendment fee of $120 is required as specified in §170.31 (7C) of 10 CFR 170, copy enclosed. Payment should be made to the U.S. Nuclear Regulatory Commission and mailed to my attention at our Washington, D.C. address.

Your application will be processed by the Region I Licensing staff located at 475 Allendale Road, King of Prussia, Pennsylvania 19406. The fee, however, is required prior to issuance of the amendment. When submitting the fee, please refer to CONTROL NUMBER 109149.

Sincerely,

Signed by:
Glenda Jackson
Glenda Jackson
License Fee Management Branch
Division of Accounting and Finance
Office of Administration and
Resources Management

Enclosure:
10 CFR 170

cc: Region I

DISTRIBUTION:
Pending Fee File
ARM/DAF R/F
LFMB R/F (2)
DW/RI/Greenville Hosp

OFFICE: ARM/LFMB
SURNAME: SKimberley:rej
DATE: 7/13/88

ARM/LFMB
GJackson
7/14/88

BETWEEN:

LICENSE FEE MANAGEMENT BRANCH, ARM
AND
REGIONAL LICENSING SECTIONS

(FOR LFMS USE)
INFORMATION FROM LTS

PROGRAM CODE: 02120
STATUS CODE: 0
FEE CATEGORY: 7C
EXP. DATE: 19921130
FEE COMMENTS: _____

LICENSE FEE TRANSMITTAL

A. REGION I

1. APPLICATION ATTACHED
   APPLICANT/LICENSEE: GREENVILLE HOSPITAL
   RECEIVED DATE: 880629
   DOCKET NO: 3008198
   CONTROL NO.: 109149
   LICENSE NO.: 29-14859-01
   ACTION TYPE: AMENDMENT

2. FEE ATTACHED
   AMOUNT: 0
   CHECK NO.: 0

3. COMMENTS

SIGNED BP
DATE 7/5/88

B. LICENSE FEE MANAGEMENT BRANCH (CHECK WHEN MILESTONE 03 IS ENTERED / T)

1. FEE CATEGORY AND AMOUNT: 7C $120

2. CORRECT FEE PAID. APPLICATION MAY BE PROCESSED FOR:
   AMENDMENT ✓
   RENEWAL _____
   LICENSE _____

3. OTHER _____
   _____

SIGNED S. Kimberly
DATE 7/12/88

MATERIALS LICENSE

Amendment No. 45

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93 – 438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	
1. Jersey City Medical Center	In accordance with application dated March 15, 1985
2. Baldwin Avenue Jersey City, New Jersey	3. License number 29-01663-01 is amended in its entirety to read as follows:
	4. Expiration date August 31, 1990
	5. Docket or Reference No. 030-02439

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35	A. Any radiopharmaceutical listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35	A. As necessary for uses authorized in Subitem 9.A.
Any byproduct material listed in Group III of Schedule A, Section 35.100 of 10 CFR 35	B. Any form listed in Group III of Schedule A, Section 35.100 of 10 CFR 35	B. 2 curies of each byproduct material authorized in Subitem 6.B.
C. Any byproduct material listed in Group IV of Schedule A, Section 35.100 of 10 CFR 35	C. Any radiopharmaceutical listed in Group IV of Schedule A, Section 35.100 of 10 CFR 35	C. As necessary for uses authorized in Subitem 9.C.
D. Any byproduct material listed in Group V of Schedule A, Section 35.100 of 10 CFR 35	D. Any radiopharmaceutical listed in Group V of Schedule A, Section 35.100 of 10 CFR 35	D. As necessary for uses authorized in Subitem 9.D.
E. Any byproduct material listed in Section 31.11(a) of 10 CFR 31	E. Prepackaged kits	E. 3 millicuries of each byproduct material authorized in Subitem 6.F.
F. Xenon 133	F. Gas or gas in solution that is the subject of an active (i.e., not withdrawn or terminated) "New Drug Application" (NDA) approved by FDA or an active (i.e., not withdrawn, terminated or on "clinical hold") "Notice of Claimed Investigational Exemption for a New Drug" (IND) that has been accepted by FDA	F. 100 millicuries

8508130355

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number: 29-01663-01
Docket or Reference number: 030-02439
Amendment No. 45

9. Authorized use

A. Any diagnostic procedure listed in Groups I and II of Schedule A, Section 35.100, Title 10, Code of Federal Regulations.
B. Preparation and use of radiopharmaceuticals for any diagnostic procedure listed in Group III of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
C. Any therapeutic procedure listed in Group IV of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
D. Any therapeutic procedure listed in Group V of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
E. In vitro studies.
F. Blood flow and pulmonary function studies.

CONDITIONS

10. Licensed material shall be used only at the licensee's facilities, Baldwin Avenue, Jersey City, New Jersey.

11. The licensee shall comply with the provisions of Title 10, Chapter 1, Code of Federal Regulations, Part 19, "Notices, Instructions, and Reports to Workers; Inspections" and Part 20, "Standards for Protection Against Radiation."

12. Licensed material listed in Item 6 above is authorized for use by, or under the supervision of, the following individual(s) for the materials and uses indicated:

Kamal C.Greiss, M.D.	Groups I, II and III In vitro studies Xenon 133 Iodine 131 for treatment of hyperthyroidism, cardiac dysfunction and thyroid carcinoma Phosphorus 32 as soluble phosphate for treatment of polycythemia vera, leukemia and bone metastases
David Chang-Sing Yang, M.D.	Groups I, II and III In vitro studies Xenon 133 Iodine 131 for treatment of hyperthyroidism, cardiac dysfunction and thyroid carcinoma
John V. Cholankeril, M.D.	Groups I, II, III, IV and V In vitro studies Xenon 133

13. Licensed material shall be used in accordance with the provisions of Section 35.14(b)(c)(e) and (f) of Title 10, Code of Federal Regulations.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number 29-01663-01
Docket or Reference number 030-02439
Amendment No. 45

(continued) CONDITIONS

14. For a period not to exceed sixty (60) days in any calendar year, a visiting physician is authorized to use licensed material for human use under the terms of this license, provided the visiting physician:

(a) Has the prior written permission of the hospital's Administrator and its Medical Isotopes Committee, and

(b) Is specifically named as a user on a Nuclear Regulatory Commission license authorizing human use, and

(c) Performs only those procedures for which he is specifically authorized by a Nuclear Regulatory Commission license.

The licensee shall maintain for the inspection by the Commission, copies of the written permission specified in subitem (a) above and of the license(s) specified in subitems (b) and (c) above. These records shall be maintained for five (5) years from the time the licensee grants its permission under subitem (a) above.

15. Patients containing Iodine 131 for the treatment of thyroid carcinoma shall remain hospitalized until the residual activity is 30 millicuries or less.

16. The licensee is authorized to hold radioactive material with a physical half-life of less than 65 days for decay-in-storage before disposal in ordinary trash provided:

A. Radioactive waste to be disposed of in this manner shall be held for decay a minimum of ten (10) half-lives.

B. Prior to disposal as normal waste, radioactive waste shall be monitored to determine that its radioactivity cannot be distinguished from background with typical low-level laboratory survey instruments. All radiation labels will be removed or obliterated.

C. Generator columns shall be segregated so that they may be monitored separately to ensure decay to background levels prior to disposal.

17. Except as specifically provided otherwise by this license, the licensee shall possess and use licensed material described in Items 6, 7, and 8 of this license in accordance with statements, representations, and procedures contained in application dated March 15, 1985 and letter dated July 5, 1985. The Nuclear Regulatory Commission's regulations shall govern the licensee's statements in applications or letters, unless the statements are more restrictive than the regulations.

For the U.S. Nuclear Regulatory Commission

Date JUL 29 1985

By Original Signed By:
John D. Kinneman
Nuclear Materials Safety and
Safeguards Branch, Region I
King of Prussia, Pennsylvania 19406